The CUMA treatment might impair angiogenesis in the tumors as detected by decreased positive staining of VEGF (Figure 4E) and CD31, a marker representing the presence of endothelial cells (Supplementary Figure S3C) compared to the PLX4032 and tumor control. Here, PECAM1 is linked to neoplasm.